Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Katkov

Gastroenterology Santa Monica, CA Medical Doctor

NPI 1386693646 CMS profile 198391

2001 Santa Monica Blvd, Suite 360W, Santa Monica, CA 90404

Open in the dashboard

General payments

$3,357

157 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Katkov of Santa Monica, CA is reported in the CMS Open Payments database as having received $3,357 across 157 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $783 35
2024 General $950 44
2023 General $481 29
2022 General $434 14
2021 General $233 12
2020 General $111 5
2019 General $364 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Katkov
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to William Katkov were reported at $783. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year William Katkov Gastroenterology median Middle half National median
2019 $364 $417 $126–$1,100 $163
2020 $111 $224 $74–$624 $114
2021 $233 $352 $106–$1,054 $132
2022 $434 $448 $129–$1,270 $149
2023 $481 $533 $150–$1,390 $160
2024 $950 $605 $160–$1,606 $164
2025 $783 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $926 43 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $554 36 payments
  3. Janssen Biotech, Inc. $341 12 payments
  4. Ardelyx, Inc. $184 6 payments
  5. Intercept Pharmaceuticals, Inc. $175 9 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $162 8 payments
  7. Regeneron Healthcare Solutions, Inc. $132 7 payments
  8. Gilead Sciences, Inc. $120 5 payments
  9. Intuitive Surgical, Inc. $106 1 payment
  10. Merck Sharp & Dohme Corporation $81 4 payments
  11. Other $576 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,273 153 payments
  2. Consulting Fee $62 3 payments
  3. Education $22 1 payment
Products named General payments · program years 2019–2025
  1. RINVOQ $531 26 payments
  2. SKYRIZI Immunology $338 17 payments
  3. XIFAXAN $318 19 payments
  4. SKYRIZI Immunology $308 13 payments
  5. STELARA $202 7 payments
  6. TRULANCE $196 15 payments
  7. IBSRELA $184 6 payments
  8. CREON $154 7 payments
  9. OCALIVA $143 7 payments
  10. TREMFYA $139 5 payments
  11. Other $1,406 62 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

565

Median for Gastroenterology: 569

Drug cost

$66,175

Median for Gastroenterology: $104,976

Branded share of claims

61.6%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 25 $25,465
Mesalamine Generic 27 $17,580
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 280 $16,712
Budesonide Ec Budesonide Brand 32 $4,158
Pantoprazole Sodium Generic 55 $873
Omeprazole Generic 59 $824
Famotidine Generic 38 $239
Dicyclomine Hcl Generic 21 $220
Nortriptyline Hcl Generic 17 $63
Ondansetron Odt Ondansetron Brand 11 $40

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$139,759

Medicare's payments for the services billed

Medicare patients

691

Average age 76

Services billed

1,348

361 women, 330 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 53%
Ischemic heart disease 40%
Diabetes 29%
Depression 26%
Cancer 23%
Atrial fibrillation 22%
Chronic kidney disease 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STELARA
  • Janssen Biotech, Inc. $147
$147 — —
RINVOQ
  • AbbVie, Inc. $109
$109 — —
TRULANCE
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $98
$98 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $96
$96 — —
SKYRIZI
  • AbbVie, Inc. $94
$94 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

157 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record